Salarius Pharmaceuticals, LLC   Report issue

For profit Phase 1 Phase 2
Founded: Houston TX United States (2010)
Status: Acquired by Flex Pharma, Inc. (2019)

Organization Overview

First Clinical Trial
2018
NCT03600649
First Marketed Drug
2018
sevelamer (renagel)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ARTHUR GRP | Salarius Pharmaceuticals, LLC

Active Ingredients

Marketed Drugs (3)

aprepitant (Emend) (2019)

busulfan (myleran) (2018)

sevelamer (renagel) (2018)

Drugs in Phase 2 Trials (1)

Key: Salarius Pharmaceuticals, LLC (0) Acquired (1)

flx-787 (4 trials)

Drugs in Phase 1 Trials (2)

Key: Salarius Pharmaceuticals, LLC (0) Acquired (2)

pembrolizumab (keytruda) (1 trial)

seclidemstat (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Endometrioid (Phase 1)

Endometrial Neoplasms (Phase 1)

Neoplasms (Phase 1)

Sarcoma (Phase 1)

Sarcoma, Ewing (Phase 1)

Overview

  • Highest Phase: None
  • # of Trials: 7
  • # of Trial APIs: 3